Department of Biochemistry, Hospital Costa del Sol, CIBER Epidemiología y Salud Pública, Universidad de Málaga, Marbella, Spain.
Adv Cancer Res. 2009;105:21-43. doi: 10.1016/S0065-230X(09)05002-7.
Breast cancer is the main cause of cancer-related death among women in Western countries. Current research is focused on identifying antiapoptotic proteins which could be a possible target for novel chemotherapeutic drugs. Secretory clusterin (sCLU) is an extracellular chaperone that has been functionally implicated in DNA repair, cell-cycle regulation, apoptotic cell death and tumorigenesis. The implication of sCLU in carcinogenesis and the progression of breast carcinomas make it an interesting gene, worthy of investigation. It has been reported to present powerful antiapoptotic activity and to perform a prosurvival function with most therapeutic treatments for breast cancer. This review summarizes our current understanding of the role of CLU in tumorigenesis, progression, and response to treatment in breast carcinomas.
乳腺癌是西方国家女性癌症相关死亡的主要原因。目前的研究集中在鉴定抗凋亡蛋白，这些蛋白可能是新型化疗药物的潜在靶点。分泌型簇蛋白 (sCLU) 是一种细胞外伴侣蛋白，在 DNA 修复、细胞周期调控、凋亡细胞死亡和肿瘤发生中具有功能意义。sCLU 在致癌作用和乳腺癌的进展中的作用使其成为一个有趣的基因，值得研究。已有报道称，sCLU 具有强大的抗凋亡活性，并在大多数乳腺癌的治疗中发挥生存促进功能。本文综述了我们目前对 CLU 在乳腺癌发生、进展和对治疗反应中的作用的认识。
